Currently, tumour stage and grade are the cornerstone indicators of prognosis in bladder cancer. Refinements in histological assessment and new molecular markers are discussed. Evidence is reviewed supporting the notion of two separate molecular pathways to bladder cancer. Deletion of candidate tumour-suppressor genes is an early and common event in primary bladder cancer.